Overall, the results provide supportive evidence for the potential value of blood‐derived GFAP as a prognostic marker for incident dementia risk in population‐based settings, which may have use for aiding stratification in clinical trials targeting the preclinical disease stage. This evidence concerns the gene GFAP and dementia.